3-(2-pyridyl)prop-2-yn-1-yl bromide hydrobromide | 54256-35-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: 3-(2-pyridyl)prop-2-yn-1-yl bromide hydrobromide
• 英文别名: 3-(pyridin-2-yl)prop-2-yn-1-yl bromide hydrobromide；1-bromo-3(2-pyridyl)-prop-2-yne hydrobromide；2-(3-bromoprop-1-ynyl)pyridine;hydrobromide
• CAS: 54256-35-8
• 化学式: BrH*C₈H₆BrN
• 分子量: 276.958
• InChiKey: IWGKHPCLBWJAII-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.41
• 重原子数：
  11
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  12.9
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-(2-pyridyl)prop-2-yn-1-yl bromide hydrobromide 、 (2RS,3SR)-3-(3-hydroxyphenyl)-3-methoxy-2-methyltetrahydrofuran 以to give (2RS,3SR)-3-methoxy-2-methyl-3-[3-(3-(2-pyridyl)prop-2-yn-1-yloxy)phenyl]tetrahydrofuran的产率得到(2RS,3SR)-3-methoxy-2-methyl-3-[3-(3-(pyridin-2-yl)prop-2-yn-1-yloxy)phenyl]tetrahydrofuran
  参考文献：
  名称：

  Quinoxalinyl derivatives suitable for use in leukotriene mediated disease

  摘要：

  本发明涉及一种公式I的杂环化合物：##STR1## 其中，Q是一个含有一个或两个氮原子的可选取代的6元单环或10元双环杂环基团；A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基；X是氧，硫，亚砜，磺酰或亚胺基；Ar是苯基，它可以可选地带有一个或两个取代基，或Ar是一个含有最多三个氮原子的可选取代的6元杂环基团；R1是氢，(1-6C)烷基，(3-6C)烯基，(3-6C)炔基，氰基-(1-4C)烷基或(2-4C)酰基，或可选取代的苯甲酰基；R2和R3一起形成一个公式--A2--X2--A3--的基团，它与A2和A3所连接的碳原子一起定义了一个具有4到7个环原子的环，其中A2和A3，可以相同也可以不同，每个都是(1-4C)烷基，X2是氧，硫，亚砜，磺酰或亚胺基；或其药学上可接受的盐。本发明的化合物是5-脂氧酶酶的抑制剂。

  公开号：

  US05236919A1
• 作为产物：
  描述：

  3-(2-吡啶基)-2-丙炔-1-醇 在 溴 、 三苯基膦 作用下， 以 二氯甲烷 为溶剂， 以58%的产率得到3-(2-pyridyl)prop-2-yn-1-yl bromide hydrobromide
  参考文献：
  名称：

  甲氧基四氢吡喃。一系列新的选择性和口服有效的5-脂氧合酶抑制剂。

  摘要：

  对（甲氧基烷基）噻唑1- [3-（萘-2-基甲氧基）苯基] -1-噻唑-2-基丙基甲基醚（1，ICI 211965）的SAR的研究导致了新系列的甲氧基四氢吡喃母体化合物4- [3-（萘-2-基甲氧基）苯基] -4-甲氧基-3,4,5,6-四氢-2H-吡喃（4f）为代表的5-脂氧合酶（5-LPO）抑制剂的制备。体外4f抑制了酵母聚糖刺激的无血浆小鼠巨噬细胞中白三烯C4（LTC4）的合成，以及A-23187刺激的人全血中的LTB4合成（IC50分别为0.5 nM和0.07 microM）。在大鼠中，在每个系统口服10 mg / kg后3小时，ED 4抑制了离体血液和经酵母聚糖发炎的空气囊渗出液中LTB4的合成，时间为ED50。在寻求更有效的口服活性化合物时，在4f同类产品中探索了在不牺牲效能的情况下降低亲脂性的策略。例如，用各种氮杂和氧杂环代用品取代4f的2-萘基，得到的化合物的log P降低了1

  DOI：

  10.1021/jm00092a010

文献信息

• Heterocyclic thiazole derivatives and pharmaceutical compositions
  申请人：Imperial Chemical Industries PLC

  公开号：US05089495A1

  公开（公告）日：1992-02-18

  The invention concerns a thiazole of the formula I, ##STR1## wherein Q.sup.1 is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents, or Ar is an optionally substituted 6-membered heterocyclene moiety continuing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or substituted (1-4C)alkyl; R.sup.2 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl or substituted (1-4C)alkyl or R.sup.2 is optionally substituted benzoyl; and Q.sup.2 is optionally substituted thiazolyl; or a pharmaceutically-acceptable salt thereof. The invention also concerns processes for the manufacture of a thiazole of the formula I and pharmaceutical compositions containing said thiazole.

  这项发明涉及一种公式I的噻唑化合物，其中Q.sup.1是一个可选择取代的含有一个或两个氮原子的6元单环或10元双环杂环基团；X是氧、硫、亚硫基、磺酰基或亚胺基；Ar是苯基，可以选择携带一个或两个取代基，或者Ar是一个可选择取代的含有最多三个氮原子的6元杂环基团；R.sup.1是氢、(1-6C)烷基、(2-6C)烯基、(2-6C)炔基或取代的(1-4C)烷基；R.sup.2是氢、(1-6C)烷基、(3-6C)烯基、(3-6C)炔基或取代的(1-4C)烷基，或者R.sup.2是可选择取代的苯甲酰基；Q.sup.2是可选择取代的噻唑基；或其药学上可接受的盐。该发明还涉及一种制备公式I的噻唑化合物的方法和含有该噻唑化合物的药物组合物。
• Heterocyclic cyclic ethers
  申请人：Imperial Chemical Industries PLC

  公开号：US05196419A1

  公开（公告）日：1993-03-23

  The invention concerns a heterocyclic cyclic ether of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 and R.sup.2 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the oxygen atom to which A.sup.2 is attached and with the carbon atom to which A.sup.3 is attached, defines a ring having 5 to 7 ring atoms, wherein A.sup.2 and A.sup.3 each is (1-3C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino, and which ring may bear one, two or three substituents; and R.sup.3 is hydrogen, (1-6C)alkyl, (2-6C)alkenyl, (2-6C)alkynyl or substituted (1-4C)alkyl; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  该发明涉及一种具有以下式I的杂环环氧化物 其中Q是含有一个或两个氮原子的可选择取代的6-成员单环或10-成员双环杂环基; A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基; X是氧，硫，亚砜，磺酰基或亚胺; Ar是苯基，可能可选择携带一个或两个取代基，或Ar是一个可选择取代的含有最多三个氮原子的6-成员杂环基; R1和R2一起形成一个具有以下式--A2--X2--A3--的基团，与A2连接的氧原子和与A3连接的碳原子一起，定义具有5至7个环原子的环，其中A2和A3各自是(1-3C)烷基，X2是氧，硫，亚砜，磺酰基或亚胺，该环可以携带一个、两个或三个取代基; R3是氢，(1-6C)烷基，(2-6C)烯基，(2-6C)炔基或取代的(1-4C)烷基;或其药用盐。该发明的化合物是5-脂氧合酶的抑制剂。
• Heterocyclic cycloalkanes
  申请人：Imperial Chemical Industries PLC

  公开号：US05217977A1

  公开（公告）日：1993-06-08

  The invention concerns a heterocyclic cycloalkane of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a (3-6C)alkylene group which, together with the carbon atom to which R.sup.2 and R.sup.3 are attached, defines a ring having 4 to 7 ring atoms, and which ring may bear one or two substituents; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  本发明涉及式I的杂环环烷化合物：##STR1## 其中，Q是含有一个或两个氮原子的可选取代的6元单环或10元双环杂环基；A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基；X是氧，硫，亚砜，磺酰或亚氨基；Ar是苯基，可以选择地带有一个或两个取代基，或Ar是一个含有最多三个氮原子的可选取代的6元杂环基；R.sup.1是氢，(1-6C)烷基，(3-6C)烯基，(3-6C)炔基，氰基-(1-4C)烷基或(2-4C)酰基，或可选取代的苯甲酰基；R.sup.2和R.sup.3共同形成一个(3-6C)烷基，与R.sup.2和R.sup.3连接的碳原子一起定义一个具有4到7个环原子的环，并且该环可以带有一个或两个取代基；或其药学上可接受的盐。本发明的化合物是5-脂氧合酶酶的抑制剂。
• Quinoxalinyl derivatives suitable for use in leukotriene mediated disease
  申请人：Imperial Chemical Industries PLC

  公开号：US05236919A1

  公开（公告）日：1993-08-17

  The invention concerns a heterocycle of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a group of the formula --A.sup.2 --X.sup.2 --A.sup.3 -- which, together with the carbon atom to which A.sup.2 and A.sup.3 are attached, defines a ring having 4 to 7 ring atoms, wherein A.sup.2 and A.sup.3, which may be the same or different, each is (1-4C)alkylene and X.sup.2 is oxy, thio, sulphinyl, sulphonyl or imino; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  本发明涉及一种公式I的杂环化合物：##STR1## 其中，Q是一个含有一个或两个氮原子的可选取代的6元单环或10元双环杂环基团；A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基；X是氧，硫，亚砜，磺酰或亚胺基；Ar是苯基，它可以可选地带有一个或两个取代基，或Ar是一个含有最多三个氮原子的可选取代的6元杂环基团；R1是氢，(1-6C)烷基，(3-6C)烯基，(3-6C)炔基，氰基-(1-4C)烷基或(2-4C)酰基，或可选取代的苯甲酰基；R2和R3一起形成一个公式--A2--X2--A3--的基团，它与A2和A3所连接的碳原子一起定义了一个具有4到7个环原子的环，其中A2和A3，可以相同也可以不同，每个都是(1-4C)烷基，X2是氧，硫，亚砜，磺酰或亚胺基；或其药学上可接受的盐。本发明的化合物是5-脂氧酶酶的抑制剂。
• Isoquinolyl, quinoxalinyl and quinazolinyl derivatives as inhibitors of
  申请人：Imperial Chemical Industries Plc

  公开号：US05446043A1

  公开（公告）日：1995-08-29

  The invention concerns a heterocyclic cycloalkane of the formula I ##STR1## wherein Q is an optionally substituted 6-membered monocyclic or 10-membered bicyclic heterocyclic moiety containing one or two nitrogen atoms; A is (1-6C)alkylene, (3-6C)alkenylene, (3-6C)alkynylene or cyclo(3-6C)alkylene; X is oxy, thio, sulphinyl, sulphonyl or imino; Ar is phenylene which may optionally bear one or two substituents or Ar is an optionally substituted 6-membered heterocyclene moiety containing up to three nitrogen atoms; R.sup.1 is hydrogen, (1-6C)alkyl, (3-6C)alkenyl, (3-6C)alkynyl, cyano-(1-4C)alkyl or (2-4C)alkanoyl, or optionally substituted benzoyl; and R.sup.2 and R.sup.3 together form a (3-6C)alkylene group which, together with the carbon atom to which R.sup.2 and R.sup.3 are attached, defines a ring having 4 to 7 ring atoms, and which ring may bear one or two substituents; or a pharmaceutically-acceptable salt thereof. The compounds of the invention are inhibitors of the enzyme 5-lipoxygenase.

  本发明涉及一种具有以下式子I的杂环环烷化合物： 其中，Q是一个含有一个或两个氮原子的可选择取代的6元单环或10元双环杂环基团；A是(1-6C)烷基，(3-6C)烯基，(3-6C)炔基或环(3-6C)烷基；X是氧，硫，亚砜，磺酰或亚胺基；Ar是苯基，它可以可选择地带有一个或两个取代基，或者Ar是一个含有最多三个氮原子的可选择取代的6元杂环基团；R1是氢，(1-6C)烷基，(3-6C)烯基，(3-6C)炔基，氰基-(1-4C)烷基或可选择取代的苯甲酰基；R2和R3一起形成一个(3-6C)烷基基团，该基团与R2和R3连接的碳原子一起定义具有4到7个环原子的环，并且该环可能带有一个或两个取代基；或其药学上可接受的盐。该发明的化合物是5-脂氧酶酶的抑制剂。